2 news items
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
ATNM
BMRN
EXEL
17 Jun 24
not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial - Long-term efficacy results in patients with active relapsed
4 Stocks to Watch in the Booming Regenerative Medicine Market
BSEM
MDXG
SNN
20 May 24
, commercial effectiveness, and disciplined expense management, positioning itself for sustained growth and long-term success. With a focus on relentless
- Prev
- 1
- Next